C
ontinued advancement in the field of medical genetics toward low-cost, and rapid next-generation sequencing, has enabled increased genetic screening for disease-causing genetic mutations, not only in patients but also in "healthy" individuals. Because of this, genetic testing has uncovered a multitude of novel unclassified genetic variants, also known as variant(s) of uncertain significance (VUS).
1,2 A VUS is a genetic change for which pathogenicity has not been confirmed. 3 Consequently, clinical genetic testing often reports VUS with ambiguous and uncertain pathogenicity. This can cause anxiety and stress in otherwise asymptomatic individuals and families who are found to carry a VUS, especially when a poorly characterized variant is erroneously reported as "likely pathogenic" or even "pathogenic." 4 VUS therefore pose serious clinical interpretation and risk-assessment challenges that limit the ability of healthcare providers to effectively counsel and treat individuals with unclear genetic predisposition to disease.
Hypertrophic cardiomyopathy (HCM), a common cause of sudden cardiac death (SCD), is a heterogeneous disease with vast genetic variability in the human genome, including a high degree of novel ("private") mutations. 5 The findings of numerous VUS associated with HCM in "healthy" populations have created ambiguity in genetic test reports, posing a growing and unresolved challenge for cardiovascular precision medicine. 6 In silico tools, such as PolyPhen2, 7 AlignGVGD, 8 and SIFT, 9 have been developed to enable the prediction of the pathogenic likelihood of gene mutations by attempting to calculate the possible impact of an amino acid substitution on protein damage. However, these are only in silico predictions, and a variant classified as "likely pathogenic" or even "pathogenic" may actually be benign. 10 Hence, it is imperative to develop new experimental systems, ideally of human origin, that can help assess the functional pathogenic potential of a VUS in a patient-specific manner.
In the case of heart disease, recent advances in induced pluripotent stem cell (iPSC) biology are generating groundbreaking opportunities for the study of genetic cardiomyopathy and familial arrhythmogenic syndromes, such as long QT, 11 catecholaminergic polymorphic ventricular tachycardia, 12 Brugada syndrome, 13 HCM, 14 and left ventricular noncompaction. 15 Cardiomyocytes derived from iPSCs (iPSC-CMs) enable recapitulation of abnormal pathogenic cardiac phenotypes in a diseaseand patient-specific manner. 16 Further strengthening this "disease in a dish" platform, the field of genome editing now allows interrogation of genetic mutations via genotype-phenotype correlation in a patient-specific manner using iPSCs. [17] [18] [19] [20] With the aid of clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 and single-stranded oligodeoxynucleotide-mediated genome editing technologies, a genetic mutation can be readily introduced or corrected in iPSCs to create isogenic patient-specific iPSC lines in a dish. 21, 22 The generated isogenic iPSC lines share the same genetic background and differ exclusively at the mutation site. This advantage eliminates confounding factors due to different genetic backgrounds, allowing the genotype-phenotype relationship to be deciphered in a more precise and measurable manner. Taken together, the powerful combination of iPSC-based disease modeling and tools such as CRISPR/Cas9-mediated genome editing present an unprecedented opportunity to study VUS functional phenotypes in a patient-specific manner.
To highlight the potential application of CRISPR/ Cas9 and iPSC disease models to clinical genetic testing, we have chosen to study a VUS with contradictory genotype-phenotype reports. The VUS is a missense variant (NM_000258.2:c.170C>A, NP_000249.1:p. Ala57Asp) in MYL3, a protein-coding gene that is a prominent component of the sarcomere complex. 23 The VUS was discovered in an asymptomatic carrier with neither clinical nor family history (3 generations) associated with suspicion of cardiac disease and sudden cardiac death (SCD). Despite the asymptomatic nature of the individual, this VUS is surprisingly predicted with confidence, using in silico tools, to be pathogenically damaging to protein function. Moreover, conflicting interpretations of pathogenicity are reported in the ClinVar database. 24 Some genetic testing resources classify this variant as a VUS, while others classify it as a likely pathogenic mutation having the potential to cause HCM. In this study, we use a combined CRISPR/ Cas9-iPSC approach to evaluate the pathogenicity of this HCM-associated VUS. These approaches will be critical in the future to mitigate patient and family anxi-
Clinical Perspective
What Is New?
• Our study demonstrates for the first time the unique potential of combining iPSC-based disease modeling and CRISPR/Cas9-mediated genome editing technology as a personalized risk-assessment platform for determining the pathogenicity of a variant of uncertain significance for hypertrophic cardiomyopathy in a patient-specific manner.
What Are the Clinical Implications?
• This personalized risk-assessment platform will help improve the study and diagnostics of a variant of uncertain significance specifically and promote implementation of precision medicine in general, better guiding clinicians in their choice of therapy and providing a clearer result for variants of uncertain significance carriers. 
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ety when confronted with unclear genetic predisposition to a disease, allowing more targeted therapies to reduce unnecessary harmful medical interventions and testing while cutting cost.
METHODS
Detailed methods are available in the Data Supplement. The data, analytic methods, and study materials for the purposes of reproducing the results or replicating procedures can be made on request to the corresponding author who manages the information.
Genomic Variant Detection in Heart
Disease-Related Genes 
Genome Editing
iPSCs were transfected with CRISPR/Cas9 and single-stranded oligodeoxynucleotide using the Lipofectamine 3000 Reagent (Thermo Fisher Scientific). For each well of a 6-well plate, 1 μg CRISPR/Cas9 vectors and 4 μg single-stranded oligodeoxynucleotide were used for transfection. For each genome edited line (isogenic corrected, isogenic homozygous VUSMYL3 (170C>A) , frameshift mutation MYL3 (170C>A/fs)
, and isogenic heterozygous MYL3 (170C>G) ), several clones were generated, 3 of which were continuously propagated and used for cardiomyocytes differentiation and characterization.
Statistical Analysis
For statistical analysis, Student's t test was used to compare the difference between 2 data sets. For comparison among multiple groups, 1-way or 2-way ANOVA was used, where appropriate, and Holm-Sidak or Tukey after tests were used for all pairwise comparisons, depending on the properties of the data sets. A P value <0.05 was considered to be statistically significant. The presented data were derived from 3 replicates, acquired from 3 differentiations performed on 3 separate occasions. All data in bar graphs were presented as mean±standard error mean.
RESULTS

Uncovering a Likely Pathogenic HCM Variant in an Asymptomatic Individual
We recruited 54 healthy individuals without clinical suspicion for heart disease from the Stanford Cardiovascular Institute iPSC Biobank, then sequenced their DNA using a custom 135 cardiomyopathy and congenital heart disease DNA panel genes associated with sudden cardiac death to determine whether they carried "pathogenic" or "likely pathogenic" mutations. 25 Based on the ClinVar annotations 24 of the resulting 592 unique nonsynonymous genetic variants across these 54 individuals, the majority (78%) were categorized as benign, likely benign or VUS ( Figure 1A in the onlineonly Data Supplement). It is interesting to note that 17 individuals each carried 1 variant annotated as "likely pathogenic," among them 4 individuals carried a "likely pathogenic" HCM-related VUS (Table I in the onlineonly Data Supplement).
Further complicating these conflicting variant findings is the fact that most individuals lack detailed family clinical histories. Out of the 4 identified "likely pathogenic" HCM VUS individuals, only 1 individual had multigenerational family members that were available and willing to undergo further echocardiography, authorize open access to their clinical and family history, and agree to a direct interview, in addition to genetic screening. We, therefore, chose to study this individual's missense variant (NM_000258.2:c.170C>A, NP_000249.1:p. Ala57Asp) in the sarcomeric gene MYL3 ( Figure 1A , 1B). It is important to note that this variant has not been previously reported in the literature and presents conflicting ClinVar reports, with some classifying the variant as a VUS and others as likely pathogenic (Table 1) .
24
MYL3 gene encodes MYL3 protein, which is an important modulator of sarcomeric myosin cross-bridge kinetics essential for the modulation of cardiac muscle contraction. 23 The A57D variant is a nonconservative amino acid substitution ( Figure 1C ), which is likely to affect secondary protein structure as these residues differ in polarity, charge, size, and other properties. 27 Missense variants in nearby residue (E56G) and at the same residue (A57G) have been reported in the Human Gene Mutation Database in association with HCM (Figure 1A) , further supporting the functional importance of this region of the protein and a strong association of this particular locus with the HCM disease. 28 The VUSMYL3 (170C>A) was then evaluated using an in silico analysis tool, PolyPhen2, on a damaging score scale of 0 to 1, 0 being benign and 1 being pathogenic (damaging to the protein function). 7 It is surprising that despite the asymptomatic cardiac history of the 46 years old VUSMYL3 (170C>A) carrier, the in silico analysis tool displayed a high score of 0.998 ( Figure 1D ), confidently 
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predicting the VUSMYL3 (170C>A) to be pathogenic and very damaging to the function of the MYL3 protein.
This was further validated using additional in silico tools (SIFT and AlignGVGD). Moreover, interrogation of this VUSMYL3 (170C>A) using the Exome Aggregation Consortium database showed that this mutation is observed in only 14 out of 121 338 individuals (Table II in the onlineonly Data Supplement), indicating again this variant is infrequent and likely pathogenic. At the carrier level, an electrocardiogram (ECG) assessment was conducted and did not detect an abnormal phenotype ( Figure 1E ). Similarly, echocardiogram did not show any evidence of hypertrophic cardiomyopathy (Table 2) . To further assess the asymptomatic nature of this HCM-associated VUSMYL3 (170C>A) , 7 family members representing 3 generations underwent Sanger sequencing. Four of the 7 family members (70, 48, 46, 11 years of age), including the studied proband, were found to carry the "likely pathogenic" VUSMYL3 (170C>A) in their genomes ( Figure 1B , 1C in the online-only Data Supplement). Similar to the proband, none of them displayed any phenotypic evidence of HCM, as is depicted by their echocardiograph results in Table 2 , nor proarrhythmic clinical history (eg, syncope or resuscitation).
Generation of an Isogenic-Corrected "Healthy" Control iPSC Line Using CRISPR/Cas9
One crucial limitation of patient-specific iPSCs as a unique tool for the study of human disease has been the inability to perform experiments under genetically ORIGINAL RESEARCH ARTICLE defined conditions. This is particularly relevant for the study of this specific VUSMYL3 (170C>A) case, as heterogeneous genetic background among individuals may disguise the subtle phenotype in vitro because of the asymptomatic nature of the VUSMYL3 (170C>A) carrier. Accordingly, in addition to the control iPSC lines derived from 2 nonconsanguineous healthy individuals, 26 an isogenic genetically corrected control line was generated from iPSCs of the heterozygous VUSMYL3 (170C>A) carrier to help evaluate disease-relevant changes. The VUSMYL3 (170C>A) carrier's peripheral blood mononuclear cells were collected and reprogrammed to iPSCs ( Figure 2 in the online-only Data Supplement). CRISPR/ Cas9 were then used to generate the isogenic corrected control cell line (Figure 2A and 2B) . Three independent isogenic corrected clones were generated and confirmed by Sanger sequencing ( Figure 2C ; Figure 3A in the online-only Data Supplement). To exclude potential off-target cuttings by CRISPR/Cas9, 10 genomic loci with the highest sequence homology to the guide RNA's binding site were checked by Sanger sequencing, separately for each 1 of the 3 clones. Sequencing results showed that the generated isogenic control cell line did not harbor any insertions or deletions at these loci (Table III in 
Interrogation of Cell Morphology and Gene Expression of the Heterozygous VUSMYL3 (170C>A) -iPSC-CMs
Multiple studies have reported myocyte sarcomere disarray and increased cell size to be features of HCM.
14,15 Therefore, to test whether the heterozygous VUSMYL3 (170C>A) -iPSC-CMs display similar sarcomeric disarray and increased cell size, we conducted immunostaining of sarcomeric proteins and cell size measurements on the VUSMYL3 (170C>A) -iPSC-CMs, and compared them to the 2 healthy controls and isogenic corrected control (consisting of 3 clones) iPSC-CMs ( Figure 3B and 3C in the online-only Data Supplement). It is interesting to note that immunostaining using sarcomere protein antibody anti-cardiac troponin T and anti-sarcomeric-α-Actinin showed that the heterozygous VUSMYL3 (170C>A) -iPSC-CMs display normal sarcomere distribution, similar to the 2 healthy controls and isogenic control iPSC-CM counterparts ( Figure 3A ; Figure 3D in the online-only Data Supplement). Furthermore, cell size analysis revealed no significant differences in cell size distribution and average cell area among the tested iPSC-CM lines (healthy controls, isogenic corrected control, and heterozygous VUSMYL3 (170C>A) ) (Figure 3B through 3D; Figure 3E in the online-only Data Supplement). Overall, iPSC-CMs carrying the HCM-associated VUSMYL3 (170C>A) do not express HCM-relevant abnormal morphological features.
Cardiomyocytes derived from HCM patients upregulate natriuretic peptide precursor A expression and have high β-myosin/α-myosin ratios. 14, 29 In addition, HCM patient-specific iPSC-CMs were previously reported to display upregulated expression of a group of genes that include NPPA, TNNT2, MYL2, MYL4, and MYH7. 14, 15 Accordingly, gene expression analysis was performed on the VUSMYL3 (170C>A) -iPSCCMs at 45 to 50 days postdifferentiation. The heterozygous VUSMYL3 (170C>A) -iPSC-CMs displayed normal gene expression similar to their control counterparts, exhibiting no increased expression of the aforementioned genes, nor an elevation of the β-myosin/α-myosin ratio ( Figure 3E ; Figure 4 in the online-only Data Supplement). Next, we further investigated the potential effect of the VUSMYL3 (170C>A) on the expression level of additional myosin light chain (MYL) genes that are highly expressed in cardiomyocytes (MYL3, MYL6, MYL7 and MYL9). 30 It is interesting to note that the heterozygous VUSMYL3 (170C>A) -iPSCCMs expressed normal gene expression for all the tested myosin light chain genes ( Figure 3E ; Figure  4 in the online-only Data Supplement). Altogether, these data show that the VUSMYL3 (170C>A) -iPSC-CMs do not display the HCM-associated phenotype at the gene expression level.
Functional Assessments of the Heterozygous VUSMYL3 (170C>A) -iPSC-CMs
HCM is caused by mutations in sarcomere genes. As such, HCM-related changes in the molecular sarcomeric motor apparatus impair cardiac function, in many cases leading to increased contractility. 31, 32 To test for potential MYL3 mutation-related functional alterations in the contractile apparatus of VUSMYL3 (170C>A) -iPSC-CMs, contractility assays were performed. Similar to the healthy control and isogenic corrected control lines, the heterozygous VUSMYL3 (170C>A) -iPSC-CMs displayed comparable contractility phenotype (Figure 4A) , without any abnormal changes in beating rate, contraction and relaxation velocities (Figure 4B through 4D; Figure 5A in the online-only Data Supplement), contraction-relaxation distance, or contractionrelaxation duration ( Figure 5B in the online-only Data Supplement).
Arrhythmia is a clinical hallmark of HCM. 33, 34 Recent studies demonstrated the ability of patient-and disease-specific iPSC-CMs to recapitulate this abnormal electrophysiological phenotype using the iPSC technology.
14,15 Accordingly, VUSMYL3 (170C>A) -iPSC-CMs were electrophysiologically assessed using a fluorescent voltage sensor with fast kinetics for imaging high-frequency electric activity, applied as a membrane voltage change indicator, known as accelerated sensor of action potentials. 35 The VUSMYL3 (170C>A) -iPSC-CMs did 
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not display a clear proarrhythmic potential ( Figure 4E ), with only 8% of the heterozygous VUSMYL3 (170C>A) -iP-SC-CMs displaying delayed after depolarizations, a percentage similar to that detected in 2 healthy controls and isogenic corrected control lines (4%, 10%, and 9%, respectively) ( Figure 4F ; Figure 5C in the onlineonly Data Supplement). In summary, in contrast with the in silico pathogenic prediction, the lack of proarrhythmic activity presented by the VUSMYL3 (170C>A) -iP-SC-CMs clearly reflects the asymptomatic nature of the VUSMYL (170C>A) carrier.
Previous studies interrogating the various mechanisms underlying arrhythmia in patients with HCM have implicated abnormal Ca 2+ homeostasis as one of the proarrhythmic mediators. 36, 37 A recent study conducted on patient-specific HCM iPSC-CMs also revealed high levels of diastolic Ca 2+ , contributing to the disease proarrhythmic nature.
14 To test for a proarrhythmic Ca 2+ -handling phenotype, we next recorded Ca 2+ transients. Compared with the 2 healthy controls and the isogenic corrected control iPSC-CMs lines, the heterozygous VUSMYL3 (170C>A) -iPSC-CMs did not exhibit ab- Figure 4G and 4H, Figure 5D in the online-only Data Supplement), in accordance with the previous electrophysiological findings. In conclusion, the genetic, morphological, and functional assessments of the heterozygous VUSMYL3 (170C>A) -iPSC-CMs all display an asymptomatic phenotype, similarly to that exhibited clinically by the VUSMYL3 (170C>A) carrier. Sarcomere immunostaining analysis of iPSC-CMs differentiated from the 2 healthy control, isogenic corrected, and heterozygous VUSMYL3 (170C>A) lines, displaying sacromeric-α-Actinin (red) and troponin T (green) stainings. Scale bars represents 10 μm (A). A schematic representation of cell size measurements using Phalloidin. Scale bars represents 150 μm (B). Distribution of iPSC-CMs size (C). iPSC-CMs size statistical analysis (n≥200 cells per line). The heterozygous VUSMYL3 (170C>A) -iPSCCMs revealed no significant difference (ns) in average cell area compared with the tested iPSC-CM lines (healthy controls-1, healthy control-2 and isogenic corrected control) (D), Gene expression analysis of differentiated iPSC-CMs at day 45 to 50 postdifferentiation. The heterozygous VUSMYL3 (170C>A) -iPSC-CMs revealed no significant difference in gene expression compared with the aforementioned tested iPSC-CM lines (E).
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Comprehensive Analysis of a Generated Isogenic Homozygous VUSMYL3 (170C>A) -iPSC Line
The heterozygous VUSMYL3 (170C>A) -iPSC-CMs did not show a pathogenic phenotype, despite a high in silico assessment score confidently predicting it to be pathogenically damaging. This predicament may be the result of the VUSMYL3 (170C>A) being a disease-causing variant in the recessive state, and therefore, explains the lack of pathogenic phenotype observed at the iPSC-CMs level. Unfortunately, because this variant is a VUS by defini- Representative contractility traces of iPSC-CMs from the two healthy control, isogenic corrected, and the heterozygous VUSMYL3 (170C>A) lines (A). Beating rate, contraction velocity, and relaxation velocity, respectively. The heterozygous VUSMYL3 (170C>A) -iPSC-CMs revealed no significant difference (ns) in beating rate, contraction velocity, and relaxation velocity, respectively, compared with the aforementioned tested iPSC-CM lines (B through D). Representative action potential traces (E).
Number of iPSC-CMs displaying proarrhythmic activity (F). Representative Ca 2+ transients (G). Number of iPSC-CMs showing proarrhythmic calcium transients (H).
Circulation. Figure 6A in the online-only Data Supplement), generating 3 independent clones for characterization. Sanger sequencing confirmed that the heterozygous VUSMYL3 (170C>A) line was turned into a homozygous VUSMYL3 (170C>A) line ( Figure 5A ; Figure  6B in the online-only Data Supplement), and no offtarget mutation was detected in the 3 homozygous VUSMYL3 (170C>A) iPSC clones (Supplemental Table IV To further confirm the benign phenotype interpretation, we generated a premature stop codon (frameshift mutation) in the healthy MYL3 allele of the heterozygous VUSMYL3 (170C>A) cell line, thus generating a cell line that lacks a healthy MYL3 allele (loss of heterozygosity) and thus, only expresses the variant allele. Three individual frameshift mutation clones were generated using the same gRNA as the generation of the homozygous VUSMYL3 (170C>A) line. To test the integrity of the frameshift mutation line, the presence of a premature stop codon in the MYL3 gene was validated by Sanger sequencing of the genomic DNA ( Figure 5B ; Figure 6C in the online-only Data Supplement). Sanger sequencing of the reverse transcription polymerase chain reaction product validated the degradation of the frameshift allele mRNA. Thus only the mutated allele mRNA was identified ( Figure 6D in the online-only Data Supplement). Next, 3 frameshift mutation clones were assessed at the genetic, morphological, and functional levels, and compared with the heterozygous VUSMYL3 (170C>A) and isogenic corrected control phenotypes. Similar to the homozygous VUSMYL3 (170C>A) line, we found no evidence of a HCM phenotype in the frameshift mutation cell line ( Figure 5C through 5L, Figure 7A through 5H in the online-only Data Supplement), further strengthening our conclusion that VUSMYL3 (170C>A) is a benign genomic variant.
Comprehensive Analysis of Symptomatic HCM iPSC-CMs Lines
To rule out the possibility that the benign prediction for the VUSMYL3 (170C>A) was simply because of a lack of sensitivity on part of the iPSC-CMs platform, we next assayed 2 different HCM disease-associated mutations, displaying severe clinical HCM-related symptoms at the carrier level, in iPSC-CMs as positive controls. To validate that the benign assessment is not the result of the inability of the iPSC-CM platform to recapitulate a pathogenic MYL3 mutation phenotype in vitro, a known autosomal dominant pathogenic mutation, MYL3 c.170C>G, at the same nucleotide position as the VUSMYL3 (170C>A) , was studied. This mutation was reported to develop a severe HCM phenotype, including SCD, with disease penetrance in 78% of the genotyped MYL3 c.170C>G mutation carriers, and an onset as early as 28 years of age. 27 For this purpose, the MYL3 c.170C>G mutation was introduced into the heterozygous VUSMYL3 (170C>A) iPSCs using CRISPR/Cas9 ( Figure  8A in the online-only Data Supplement). Accordingly, 3 independent iPSC clones (named MYL3 (170C>G) ) were generated and were tested by Sanger sequencing to confirm that the MYL3 c.170C>A variant allele was replaced with the MYL3 c.170C>G mutation ( Figure 6A ; Figure 8B in the online-only Data Supplement) without off-target cutting (Table V in the online-only Data Supplement). Next, to further elucidate the capability of the iPSC-CMs platform to recapitulate a pathogenic phenotype of a symptomatic carrier, a heterozygous HCM missense genetic variant in the sarcomeric gene MYB-PC3 (MYBPC3 c.961G>A, p.Val321Met) ( Figure 6A ) was studied using a carrier-specific iPSC-CMs line. Note that the carrier presented an early HCM onset at the young age of 23 years (Table 2) , is implanted with a cardioverter defibrillator, and has a strong family history of SCD, as early as 34 years of age.
The iPSC lines were then evaluated for pathogenic morphological changes and functional proarrhythmic potential. Similar to the heterozygous VUSMYL3 (170C>A) -iPSC-CMs, both MYL3 (170C>G) -and MYBPC3 (961G>A) -iPSCCMs exhibited no significant difference in cell size (Figure 6B ; Figure 8C in the online-only Data Supplement) and had normal sarcomere distribution ( Figure 8D ORIGINAL RESEARCH ARTICLE TNNT2, MYL2, and MYH7), these HCM-related genes, including the β-myosin/α-myosin ratio, were elevated in the MYL3 (170C>G) -and MYBPC3 (961G>A) -iPSC-CMs (Figure 6C ; Figure 8E in the online-only Data Supplement). While both MYL3 (170C>G) -and MYBPC3 (961G>A) -iPSC-CMs did not exhibit a change in expression level of the myosin light chain genes (MYL2, MYL3, MYL6, MYL7 and MYL9) in comparison to the isogenic corrected and heterozygous VUSMYL3 (170C>A) -iPSC-CMs, a significant increase in the MYL4 expression was noted ( Figure 6C ), as has been previously reported by multiple HCM-related studies. [38] [39] [40] Contractility measurements did not display a statistically significant difference in beating rate among the tested lines ( Figure 6D ; Figure 8F in the online-only Data Supplement). Both MYL3 (170C>G)-and MYBPC3 (961G>A) -iPSC-CMs displayed faster contraction velocity in comparison to the corrected isogenic control line and heterozygous VUSMYL3 (170C>A) -iPSCCMs ( Figure 6E ; Figure 8F in the online-only Data Supplement). MYL3 (170C>G) -iPSC-CMs displayed faster relaxation velocity ( Figure 6F ; Figure 8F in the onlineonly Data Supplement), as previously documented for this specific MYL3 (170C>G) gene mutation, 41, 42 and as validated in this study by 3 independent MYL3 (170C>G) -iPSC-CMs clones. The MYBPC3 (961G>A) -iPSC-CMs did not exhibit a significant difference in relaxation velocity compared with the isogenic corrected control and heterozygous VUSMYL3 (170C>A) -iPSC-CMs ( Figure 6F ). It is notable that although only 8% of heterozygous VUSMYL3 (170C>A) -iPSC-CMs displayed a proarrhythmic electrophysiological phenotype in the form of delayed after depolarizations ( Figure 4F ), 42% and 46% of the MYL3 (170C>G) -and MYBPC3 (961G>A) -iPSC-CMs, respectively, exhibited delayed after depolarizations, displaying higher amplitude and shorter coupling intervals (Figure 6G and 6I; Figure 8G in the online-only Data Supplement). In addition, both presented significant variability in beat-to-beat intervals of action potentials ( Figure 6H ), another notable proarrhythmic characteristic. In accordance with the electrophysiological findings, 37% and 47% of the MYL3 (170C>G) -and MYBPC3 (961G>A) -iPSC-CMs, respectively, exhibited an abnormal Ca 2+ phenotype, presenting double-peaked Ca 2+ transients (Figure 6J and 6K; Figure 8H in the online-only Data Supplement) that were previously shown to be a proarrhythmic manifestation in HCM iPSC-CM 14 , as well as in another familial arrhythmogenic syndrome iPSC-CM study. 12 These events were virtually absent in the VUSMYL3 (170C>A) -iPSC-CMs. It is important to note that Fura2 Ca 2+ imaging further demonstrated a significant increase in diastolic Ca Taken together, similarly to the symptomatic nature of both MYL3 (170C>G) and MYBPC3 (961G>A) carriers, an evident symptomatic functional phenotype was recapitulated by the MYL3 (170C>G) -and MYBPC3 (961G>A) -iPSC-CMs, respectively, highlighting the potential of the iPSC-CM platform to successfully assess both pathogenic and benign phenotypes.
DISCUSSION
In this study, we combine the powerful strengths of iPSC-based disease modeling and CRISPR/Cas9-mediated genome editing technology to demonstrate their unique potential as a personalized VUS risk-assessment platform for determining the pathogenicity of VUS. To highlight the dilemma and uncertainty that VUS presents for patients and clinicians around the world, we screened dozens of "healthy" individuals in search of a VUS that can clearly showcase the uncertainty surrounding genomic variant interpretation: a variant in a healthy individual that is annotated as "likely pathogenic." By combining both aforementioned technologies for the study of such a VUS (MYL3 c.170C>G associated with HCM), we were able to (1) recapitulate the asymptomatic phenotype of the VUSMYL3 (170C>A) carrier by showing a lack of HCM-related gene expression profile, morphological phenotype, and proarrhythmic activity in the heterozygous VUSMYL3 (C>A) -iPSC-CMs; (2) confirm the asymptomatic clinical phenotype as a benign assessment in a genome-edited isogenic homozygous VUSMYL3 (170C>A) line, as well as in a heterozygous frameshift mutation MYL3 (170C>A/fs) line; and (3) validate the ability of the combined iPSC-CMs and genome-editing platform to recapitulate a pathogenic phenotype of a symptomatic carrier.
HCM is a prevalent hereditary cardiac disorder linked to arrhythmia and SCD by both animal models and patient-specific iPSC-CMs studies. 14, 15, 43 In contrast to these models, the carrier-specific VUSMYL3 (170C>A) -iPSC-CMs did not display a proarrhythmic phenotype. To validate whether the observed asymptomatic nature of the VUSMYL3 (170C>A) -iPSC-CMs is the result of a recessive missense mutation, we also generated a homozygous VUSMYL3 (170C>A) line. It is interesting to note that similar to the heterozygous cells, the phenotype displayed by all 3 homozygous iPSC-CMs clones was an asymptomatic one as well. The as- ORIGINAL RESEARCH ARTICLE ymptomatic assessment of the homozygous line was further strengthened by an asymptomatic phenotype detected in the genome-edited heterozygous frameshift mutation MYL3 (170C>A/fs) line (expressing solely the c.170C>A variant allele). Collectively, these data confirm that the lack of pathogenic phenotype in heterozygous VUSMYL3 (170C>A) -iPSC-CMs was not the result of a recessive gene.
HCM is a complex and heterogeneous disease encompassing a wide variety of mutations and variants. 29, 32 To validate whether the benign asymptomatic assessments of both the heterozygous VUSMYL3 (170C>A) and the genome-edited homozygous VUSMYL3 (170C>A) -iPSC-CMs are not the result of a potential inability on part of the iPSC-CMs platform to recapitulate a pathogenic MYL3 mutation phenotype, we genomeedited iPSCs with a known disease-causing mutation in the MYL3 gene (MYL3 c.170C>G), at the same nucleotide position as the VUSMYL3 (170C>A) . 27 Next, to further test the sensitivity of this cellular platform to recapitulate a HCM VUS, iPSCs from an HCM patient with a MYBPC3 c.961G>A variant were generated from a carrier presenting classical clinical HCM symptoms. We found that both the MYL3 (170C>G) -and MYBPC3 (961G>A) -iPSC-CMs did show a HCM-pathogenic phenotype; for example, upregulation of HCM-related genes expression, elevation in β-myosin/α-myosin ratio, irregular contractility, proarrhythmic electrophysiological phenotype (delayed afterdepolarization), and an abnormal Ca 2+ phenotype, similar to the results from previous HCM iPSC-CMs and HCM animal studies. 14, 15, 41, 44, 45 The HCM-related phenotypes observed in both the MYL3 (170C>G) -and MYBPC3 (961G>A) -iPSCCMs, effectively demonstrate that the lack of phenotype exhibited by both the heterozygous and homozygous VUSMYL3 (170C>A) -iPSC-CMs was not due to a technical artifact or faulty detection sensitivity on part of the iPSC-CMs platform, but rather a reflection of a benign phenotype.
Over the past decade, a large range of studies, using similar assays to those presented in the current study, have demonstrated the intriguing ability of the iPSCCMs platform to recapitulate disease phenotype presented by the patient at bedside at the patient-derived cellular level in the dish, as been previously reported for genetic cardiomyopathy and arrhythmogenic syndromes such as: long QT, catecholaminergic polymorphic ventricular tachycardia, Brugada syndrome, familial dilated cardiomyopathy, and HCM. 11, 12, 14, 15, 46 Similarly, iPSC-CMs have been also shown to recapitulate a normal "healthy" phenotype in cells derived from "healthy" subjects, as documented by countless studies. This striking recapitulation capability of the iPSC-CMs platform is also vivid in this study. The chosen carrier is a healthy 46-year-old, active, athletic individual, that although has been phenotyped with a "likely pathogenic" HCM MYL3 c.170C>A VUS, does not have a clinical cardiac history, presents normal ECG, and normal echocardiography results. Further, supporting the asymptomatic nature of the carrier is the carrier's impressive family history, consisting of 3 generations of asymptomatic carriers as old as 70 years of age. It is impressive that the proband-derived cells reflect the proband's asymptomatic nature. In a similar manner, in the case of the MYL3 (170C>G) mutation, the cells also strikingly recapitulated the carriers' clinical phenotype. MYL3 (170C>G) mutation carriers have been shown to experience HCM-related symptoms including SCD, with disease penetrance of 78%, and an onset as early as 28 and as late as 38 years of age. The genome-edited MYL3 (170C>G) -iPSC-CMs nicely recapitulate the symptomatic nature of the carriers. Reinforcing these findings, an additional carrier displaying a HCM variant that demonstrates a clinical HCM onset as early as 23 years of age and a family history of SCD at an age as young as 34 was studied. In this case, the carrier-derived iPSC-CMs were also able to recapitulate a pathogenic phenotype. Altogether, the presented evidence here demonstrates the capability of the carrier-specific iPSC-CMs platform to reveal both a benign and pathogenic phenotype of prospective variants in a manner that recapitulates the carrier's clinical presentation.
Collectively, our data demonstrate the unique potential of combining iPSC-based disease modeling and CRISPR/Cas9-mediated genome editing technology as a personalized VUS risk assessment platform that can facilitate the study of the growing VUS phenomenon. Linking together iPSC and genome editing technologies presents an unprecedented opportunity to elucidate the pathogenicity of VUS in a dish in a carrier-specific manner. It is important to note that these efforts will help improve the study and diagnostics of VUS specifically and the promotion of personalized and precision medicine in general, better guiding clinicians in their choice of therapy and providing a clearer result for the VUS carriers.
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The online-only Data Supplement is available with this article at https://www. ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.117.032273. D through F) . Representative action potentials traces displaying delayed after depolarizations (highlighted by red vertical arrows) and varying interbeats intervals (indicated by red horizontal arrows) recorded from MYL3 (170C>G) and MYBPC3 (961G>A) iPSC-CMs, respectively (G, H). Number of MYL3 (170C>G) and MYBPC3 (961G>A) iPSC-CMs displaying proarrhythmic activity (I). Representative Ca 2+ transients displaying delayed after depolarizations (J). Number of MYL3 (170C>G) and MYBPC3 (961G>A) iPSC-CMs depicting proarrhythmic calcium transients (K). *P<0.1, **P<0.01, ***P<0.001, ****P<0.0001, compared with isogenic corrected and heterozygous VUSMYL3 (170C>A) lines.
